Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

被引：0
|
作者：
Kavanagh, Simon
Heath, Emily
Hurren, Rose
Barghout, Samir H.
Liyanage, Sanduni U.
Siriwardena, Thirushi
Claudio, Jaime
Zhang, Tong
Sukhai, Mahadeo
Stockley, Tracy L.
Kamel-Reid, Suzanne
Rostom, Amr
Khalaf, Dina
Lutynski, Andrzej
Rydlewski, Anna
Schuh, Andre C.
Gupta, Vikas
Sibai, Hassan
Maze, Dawn
Chan, Steven M.
Schimmer, Aaron D.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2596
引用
收藏
页数：3
相关论文
共 5 条
  • [1] AML refractory to primary induction with Ida-FLAG has a poor clinical outcome
    Kavanagh, Simon
    Heath, Emily
    Hurren, Rose
    Gronda, Marcela
    Barghout, Samir H.
    Liyanage, Sanduni U.
    Siriwardena, Thirushi P.
    Claudio, Jaime
    Zhang, Tong
    Sukhai, Mahadeo
    Stockley, Tracy L.
    Kamel-Reid, Suzanne
    Rostom, Amr
    Lutynski, Andrzej
    Khalaf, Dina
    Rydlewski, Anna
    Chan, Steven M.
    Gupta, Vikas
    Maze, Dawn
    Sibai, Hassan
    Schuh, Andre C.
    Yee, Karen
    Minden, Mark D.
    Schimmer, Aaron D.
    [J]. LEUKEMIA RESEARCH, 2018, 68 : 22 - 28
  • [2] Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
    Wang, Ling
    Devillier, Raynier
    Wan, Ming
    Decroocq, Justine
    Tian, Liang
    Furst, Sabine
    Wang, Li-Ning
    Vey, Norbert
    Fan, Xing
    Blaise, Didier
    Hu, Jiong
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 (03) : 458 - 464
  • [3] Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
    Ling Wang
    Raynier Devillier
    Ming Wan
    Justine Decroocq
    Liang Tian
    Sabine Fürst
    Li-Ning Wang
    Norbert Vey
    Xing Fan
    Didier Blaise
    Jiong Hu
    [J]. Bone Marrow Transplantation, 2019, 54 : 458 - 464
  • [4] Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
    Li, Limin
    Zhang, Xiaoqian
    Yu, Hongjuan
    Zhang, Mingwen
    Xu, Mengyuan
    Liu, Jie
    Fu, Yueyue
    Meng, Hongbin
    Lyu, Chengfang
    Li, Xiaoxia
    Zhou, Jin
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 6863 - 6870
  • [5] Concordance between Bone Marrow and Peripheral Blood Samples for Assessment of FLT3 Internal Tandem Duplication (ITD) Mutations: Data from Patients Screened for Participation in Quantum-R, a Global, Randomized, Open-Label, Phase 3 Study Examining the Effect of Quizartinib Monotherapy Vs Salvage Chemotherapy on Overall Survival in Patients with FLT3 - ITD - Mutated AML Who Are Refractory to or Have Relapsed after First-Line Therapy
    Khaled, Samer
    Ganguly, Siddhartha
    Perl, Alexander E.
    Kobayashi, Ken
    Berisha, Flora
    Ding, Wei
    Lameh, Jelveh
    Martinelli, Giovanni
    [J]. BLOOD, 2017, 130
1